Patents Assigned to Merck
  • Psyllium-hydrocolloid gum composition
    Patent number: 6312730
    Abstract: A rapidly dispersible powder having use as a laxative and fiber supplement, comprising psyllium particles coated with gum arabic. The present invention also includes a method for making the powder that includes providing an effective quantity of gum arabic to a fluidized bed having the psyllium particles to make the rapidly dispersible powder. The present invention further includes a method for making a constipation treatment and a treatment for fiber supplementation.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: November 6, 2001
    Assignee: Johnson & Johnson. Merck Consumer Pharmaceuticals, Co.
    Inventor: Eugene H. Sander
  • Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors
    Patent number: 6313125
    Abstract: 1,2,4-triazolo[4,3-b]pyridazine derivatives are ligands for GABAA receptors useful in the treatment of disorders of dementing illnesses.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: November 6, 2001
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, Kevin William Moore, Austin John Reeve
  • Biologically resorbable polymerization products made of binding agent systems which can be hardened by radiation
    Patent number: 6313189
    Abstract: Described herein are methods for preparing bioabsorbable polymerization products having interconnecting pore structure by polymerizing compositions containing ethylene glycol- or glycero-oligoester(meth)acrylates monomers and, optionally, other components. The polymerization products are particularly useful for dental lacquers, dental inlays and shaped articles which are bioabsorbable and exhibit an interconnecting pore structure.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: November 6, 2001
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Robert Wenz, Berthold Nies
  • Tyrosine kinase inhibitors
    Patent number: 6313138
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 6, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hartman
  • Spiro-indolines as Y5 receptor antagonists
    Patent number: 6313298
    Abstract: Compounds of general structural formula I such as that shown in structural formula II are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: November 6, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ying-Duo Gao, Lihu Yang, Douglas J. MacNeil, Nancy R. Morin, Takehiro Fukami, Takahiro Fukuroda, Akio Kanatani, Yasuyuki Ishii, Masaki Ihara
  • Pharmaceutical tablets
    Publication number: 20010036475
    Abstract: The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.
    Type: Application
    Filed: June 14, 2001
    Publication date: November 1, 2001
    Applicant: MERCK & CO., Inc.
    Inventors: Tzyy-Show H. Chen, Thomas G. Nyairo, Ashok V. Katdare
  • Halophenoxy substituted carbapenem antibacterial compounds
    Patent number: 6310055
    Abstract: The present invention relates to carbapenem antibacterial agents in which the carbapenem nucleus is substituted at the 2 -position with a iodophenoxy linked through a group —Z—CH2—; The compound is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: wherein Z represents trans-ethenediyl or ethynediyl. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: October 30, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Kevin D. Dykstra
  • Benzonitriles and benzofluorides
    Patent number: 6310068
    Abstract: Compound of the formula I in which Q and Ar have the meanings indicated herein, and their salts, exhibit actions on the central nervous system.
    Type: Grant
    Filed: April 5, 1996
    Date of Patent: October 30, 2001
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Henning Böttcher, Karl Ulrich Bühring, Hartmut Greiner, Gerd Bartoszyk, Christoph Seyfried
  • Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands
    Patent number: 6310203
    Abstract: Substituted 1,2,4-Triazolo[3,4-A]phthalazine derivatives that are GABA Alpha 5 ligands are prepared from compounds represented by the formula: in which R1 is hydrogen, halogen, CF3, OCF3, CN or an optionally substituted C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy group; R2 is hydrogen, halogen, CF3, OCF3, CN or an optionally substituted C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy group; Z is an optionally substituted 5-membered or 6-membered heteroaromatic ring; and G is a leaving group.
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: October 30, 2001
    Assignee: Merck Sharpe & Dohme Limited
    Inventors: William Robert Carling, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Kevin William Moore, Francine Sternfeld, Leslie Joseph Street
  • Alkylspiroborate salts for use in electrochemical cells
    Publication number: 20010033964
    Abstract: The invention relates to a process for the preparation of borate salts, and to their use in electrochemical cells.
    Type: Application
    Filed: January 12, 2001
    Publication date: October 25, 2001
    Applicant: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Udo Heider, Michael Schmidt, Andreas Kuehner, Andrea Schmenger
  • Tyrosine kinase inhibitors
    Patent number: 6306874
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: October 23, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Stable aqueous formulation of 3-(N-butylacetamino)-propionic acid ethyl ester
    Patent number: 6306905
    Abstract: The present invention relates to stable aqueous formulations of the insect repellent ethyl 3-(N-butyl-acetamino)propionate.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: October 23, 2001
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Thekla Kurz, Sabine Hitzel, Dorothee Wille, Mohammad Jalalian
  • HIV integrase inhibitors
    Patent number: 6306891
    Abstract: Nitrogen-containing heteroaryl dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: October 23, 2001
    Assignees: Merck & Co., Inc., Tularik Inc.
    Inventors: Harold G. Selnick, Melissa Egbertson, Daria Jean Hazuda, James P. Guare, Jr., John S. Wai, Steven D. Young, David L. Clark, Julio C. Medina
  • Bradykinin B1 receptor antibodies
    Patent number: 6307027
    Abstract: DNAs encoding bradykinin B1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind desArg10 kallidin and other B1-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: October 23, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
  • Laser-markable paper and board products
    Patent number: 6306493
    Abstract: There is provided laser-markable paper and board products which include micronized polymers comprising of linear aromatic polyesters and/or of linear polyarylenes having a particle size of from 0.1 to 100 &mgr;m as absorber material and material for carbonization.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: October 23, 2001
    Assignee: Merck Patent Gesellschaft
    Inventor: Alexandra Brownfield
  • Prostaglandin receptor ligands
    Publication number: 20010031766
    Abstract: Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed.
    Type: Application
    Filed: February 12, 2001
    Publication date: October 18, 2001
    Applicant: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Nicholas Lachance, Marc Labelle, Michel Gallant, Nathalie Chauret, Laird A. Trimble
  • Ultraviolet absorbent
    Publication number: 20010031272
    Abstract: To provide an ultraviolet absorbent having high UV shieldability, especially UV-A shieldability, high transparency and good dispersibility.
    Type: Application
    Filed: April 23, 2001
    Publication date: October 18, 2001
    Applicant: Merck Patent Gesellschaft mit Beschrankt
    Inventors: Tamio Noguchi, Yukitaka Watanabe
  • 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
    Patent number: 6303593
    Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Christopher Forbes, Shouwu Miao, William H. Parsons, Kathleen Rupprecht, Frank Kayser
  • Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
    Patent number: 6303753
    Abstract: DNA encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing the DNA, methods for producing &agr; and &bgr; subunits and isolated or substantially pure &agr;4, &agr;7 and &bgr;4 subunits are provided. In addition, cells that expresses these subunits singly or combination with other subunits of nicotinic acetylcholine receptors and methods using the cells are provided.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Elliott, Steven B. Ellis, Michael M. Harpold
  • Heterocyclic potassium channel inhibitors
    Patent number: 6303637
    Abstract: The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson